Business Wire

Sigfox France Demonstrates the 0G Potential in Response to the Scheduled Shutdown of the Public Switched Telephone Network (PSTN)

14.5.2019 14:35:00 EEST | Business Wire | Press release

Share

Within three years, all switched networks will have disappeared and most of them will be replaced by exchanges based on the IP protocol, with or without wires. This standardization of exchanges allows substantial gains in telecommunications infrastructures, but it generates significant costs for migrating from existing solutions based on switched networks. A lot of equipment will have to be adapted or replaced without creating added value or new services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005512/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The MutaKom box (Photo: Sigfox)

In order to meet this major challenge, which will impact millions of devices, Sigfox, the world's leading IoT service provider and first global 0G network operator, and J2C, a specialist in service offerings in the security market, have developed the MutaKom box, which replaces the previous wiring that linked the devices to the PSTN. The MutaKom solution offers immediate service continuity and is economically unbeatable.

The PSTN still satisfies multiple uses including: telemetry, remote reading, remote monitoring of premises, remote maintenance or remote alarms of machines, gauges, industrial automatons and alarm centres. All these equipments amount to a fleet of several million units, in France only, which will quickly need to find a simple, immediate and inexpensive alternative link.

The market for alarm control units in France only is estimated at 1.2 million (GPMSE and ADMS sources). The stakes around the termination of the PSTN are therefore crucial. With MutaKom providing an optional backup battery, alarm centres will maintain a similar energy autonomy, while increasing security against hacking or sabotage attempts. Indeed, the wireless link provided by the Sigfox 0G network is resistant to all types of jammers, and makes it impossible to cut the telephone cable to isolate the alarm from the remote monitor.

As Patrick Cason, Managing Director at Sigfox France, points out: "We are targeting a large market in Europe with millions of alarm centres and other technical equipment for which the only solution, before the arrival of the MutaKom offer, was to migrate to more expensive equipment without real added value. With this in mind, MutaKom is, in our opinion, the most competitive offer on the market”.

Christophe Sautter, Executive President of the GIP Group (Générale Industrielle de Protection), first security player in France to test the MutaKom solution: "The first tests were more than convincing. We believe that the simplicity of implementation and cost savings will be significant with a tangible impact on customer satisfaction”.

This Sigfox network application illustrates once again the potential of the 0G network to permanently or temporarily compensate for the unavailability of existing networks. The 0G standard is there to provide a minimal and functional link to serve the successive changes in telecommunications networks, which tend to become more complex in order to deliver ever more speed, while usage remains simple.

More information on MutaKom offer: www.mutakom.fr

About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.

Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France, and also has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.

About J2C
J2C is a new French player, based in Montpellier, created by specialists in the security and telecommunications market, whose mission is to propose new service offers on the security market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye